Nursing CPD Institute

Alpha-1 Antitrypsin Clinical Practice Guidelines

CPD Hours: 1
Current as at 05 October 2021
AATD is a rare genetic condition estimated to affect approximately 1 in 300 people in Australia. Early symptoms are often misdiagnosed as asthma, with an accurate diagnosis often taking several years.

Categories: ,

Tags:

“Explore medicine prescribing and administration in the palliative patient”

Course Content

AATD is a rare genetic condition estimated to affect approximately 1 in 300 people in Australia. Early symptoms are often misdiagnosed as asthma, with an accurate diagnosis often taking several years.

Alpha-1 Antitrypsin deficiency (AATD) is a genetic condition that may result in lung and/or liver disease. Alpha-1 Antitrypsin is a protein whose primary function is to protect the lungs from neutrophil disease.

Learning Outcomes

In this session, you will:

  • Review the recommended Clinical Practice Guidelines for Alpha-1
  • Define Alpha-1 Antitrypsin Deficiency
  • Understand the challenges of diagnosis & treatment for Alpha-1 patients
  • Acquire knowledge about the recommended treatment pathways for Alpha-1 patients
The Nursing CPD Institute

Join NCPDI to access this content.


Join Now

Login if you already have an account.


Login